Online inquiry

IVTScrip™ mRNA-Anti-KDR, SSS-23(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15082MR)

This product GTTS-WQ15082MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets KDR gene. The antibody can be applied in Glioblastoma research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NM_002253.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3791
UniProt ID P35968
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-KDR, SSS-23(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ15082MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1005MR IVTScrip™ mRNA-Anti-SLAMF7, ABBV-383(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-383
GTTS-WQ14709MR IVTScrip™ mRNA-Anti-SELP, SEG101(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA SEG101
GTTS-WQ14897MR IVTScrip™ mRNA-Anti-stx2 A-subunit, Shigamabs®(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA Shigamabs®
GTTS-WQ2509MR IVTScrip™ mRNA-Anti-CALCRL, AMG 334(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 334
GTTS-WQ11394MR IVTScrip™ mRNA-Anti-PDGFRA, MEDI-575(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI-575
GTTS-WQ3598MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1129980(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BAY 1129980
GTTS-WQ15881MR IVTScrip™ mRNA-Anti-SLC34A2, XMT-1536(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA XMT-1536
GTTS-WQ13216MR IVTScrip™ mRNA-Anti-TNFRSF9, PF-05082566(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA PF-05082566
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW